Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P010047/S073

PROGEL Pleural Air Leak Sealant

Neomend, Inc. · Decision date Mar 12, 2026

FDA DECISIONP010047/S073

What did the FDA decide?

FDA records P010047/S073 as a supplement to PMA P010047, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Mar 12, 2026.

FDA approval order statement

For the reduction of testing frequency for Air Flow Test, Standard Spray Tips and Extended Spray Tips; removal of Neomend Inc. Pouch Peel Strength Testing for Incoming Packaging Materials with the adoption of Supplier-Performed ASTM F88 Testing for Chevron Seal Pouches; and elimination of SDS-PAGE Lot Release Testing
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Anesthesiology
Decision date
Mar 12, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P010047/S073
Regulatory pathway
PMA supplement
Applicant
Neomend, Inc.
Product code
NBE
Decision code
OK30
Decision date
Mar 12, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Sealant, polymerizing.

Applicant
Neomend, Inc.
Product code
NBE
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P010047/S072 · Related supplement

    PROGEL Pleural Air Leak Sealant

  2. P010047/S073 received

    Application receipt date recorded by FDA.

  3. P010047/S073 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P010047. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P010047

Product / regulatory recordCompanyPathwayDecision dateSource
Neomend, Inc.PMA supplementDec 18, 2025FDA

Explore the linked device profile

Other records with product code NBE

Product / regulatory recordCompanyPathwayDecision dateSource
Neomend, Inc.PMA supplementMar 12, 2026FDA
Baxter Bio SciencePMA supplementDec 18, 2025FDA
Neomend, Inc.PMA supplementDec 18, 2025FDA
Coseal Spray SetP030039/S031
Baxter Bio SciencePMA supplementAug 21, 2025FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Neomend, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
60 Technology Dr., Irvine, CA, 92618

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records